ACC.26

北京時(shí)間3月28日至31日，由美國(guó)心臟病學(xué)會(huì)（ACC）舉辦的心血管領(lǐng)域盛會(huì)——ACC.26學(xué)術(shù)會(huì)議將在美國(guó)新奧爾良隆重舉行。作為全球頂尖心血管學(xué)術(shù)盛會(huì)，ACC年會(huì)將匯聚來(lái)自全球的20，000余名專業(yè)人士，通過(guò)互動(dòng)式研討、學(xué)術(shù)交流及產(chǎn)品博覽會(huì)等形式，推動(dòng)心血管領(lǐng)域的創(chuàng)新發(fā)展。

本次會(huì)議特別值得關(guān)注的是，多位中國(guó)心血管研究專家將報(bào)告其團(tuán)隊(duì)的重要研究成果，展現(xiàn)中國(guó)學(xué)者在國(guó)際頂尖學(xué)術(shù)舞臺(tái)上的影響力。其中，中國(guó)人民解放軍東部戰(zhàn)區(qū)總醫(yī)院唐春香教授與郭翔教授、中國(guó)醫(yī)學(xué)科學(xué)院阜外醫(yī)院康連鳴教授將分別報(bào)告其團(tuán)隊(duì)在冠狀動(dòng)脈疾病無(wú)創(chuàng)評(píng)估、人群篩查及心肌病治療領(lǐng)域的前沿成果。

具體日程讓我們一起先睹為快！

01

重要指南更新值得關(guān)注

除了前沿臨床研究，本次會(huì)議將發(fā)布：

·2026年血脂異常管理指南

·2026年急性肺栓塞指南

這些指南將為臨床實(shí)踐提供重要參考，促進(jìn)心血管疾病診療的標(biāo)準(zhǔn)化和規(guī)范化。

02

最新突破性臨床試驗(yàn)（LBCT）

LBCT I

北京時(shí)間：3月28日 23:30-00:30

Ultrasound-Facilitated Catheter-Directed Thrombolysis Vs Anticoagulation Alone For Acute Intermediate-High-Risk Pulmonary Embolism: Primary Results of the HI-PEITHO Randomized Clinical Trial

急性中高危肺栓塞超聲輔助導(dǎo)管導(dǎo)向溶栓對(duì)比單純抗凝治療：HI-PEITHO隨機(jī)臨床試驗(yàn)主要結(jié)果

匯報(bào)人：Stavros V. Konstantinides

Outcomes in Patients With Atrial Fibrillation Randomized to Receive Left Atrial Appendage Closure or Oral Anticoagulation: Primary Results of the CHAMPION-AF Clinical Trial

比較隨機(jī)接受左心耳封堵術(shù)或口服抗凝治療的房顫患者的結(jié)局：CHAMPION-AF臨床試驗(yàn)的主要結(jié)果

匯報(bào)人：Saibal Kar

Primary Left Ventricular Unloading in Anterior ST-Segment Elevation Myocardial Infarction (STEMI) Without Cardiogenic Shock: Results From the STEMI-Door to Unload Randomized Clinical Trial

無(wú)心源性休克前壁ST段抬高型心肌梗死的早期左心室減負(fù)荷治療：STEMI-Door to Unload隨機(jī)臨床試驗(yàn)結(jié)果

匯報(bào)人：Navin Kapur

LBCT II

北京時(shí)間：3月29日 5:45-6:45

Kardinal: A Phase 2 Study of Tonlamarsen For the Treatment of Uncontrolled HypertensionKARDINAL

研究：評(píng)估Tonlamarsen治療未控制高血壓的2期臨床試驗(yàn)

匯報(bào)人：Luke Laffin

Evolocumab in Patients Without Significant Atherosclerosis: Results From VESALIUS-CV

依洛尤單抗在無(wú)顯著動(dòng)脈粥樣硬化患者中的應(yīng)用：VESALIUS-CV研究結(jié)果

匯報(bào)人：Nicholas Marston

Intensive Low-Density Lipoprotein Cholesterol Targeting in Patients With Atherosclerotic Cardiovascular Disease

動(dòng)脈粥樣硬化性心血管疾病患者強(qiáng)化低密度脂蛋白膽固醇目標(biāo)值探索

匯報(bào)人：Yong-Joon Lee

DASH-Patterned Groceries to Reduce Blood Pressure Among Adults With Treated Hypertension: Results From the GoFreshRx Randomized Clinical Trial

為經(jīng)治療的高血壓成人提供DASH模式食品以降低血壓：GoFreshRx隨機(jī)臨床試驗(yàn)結(jié)果

匯報(bào)人：Stephen Paul Juraschek

LBCT III

北京時(shí)間：3月29日 22:30-23:30

Controlled Trial of High-Risk Coronary Intervention With Percutaneous Left Ventricular Unloading (CHIP-BCIS3)

高危冠狀動(dòng)脈介入治療中經(jīng)皮左心室減負(fù)荷技術(shù)的對(duì)照試驗(yàn)：CHIP-BCIS3研究

匯報(bào)人：Divaka Perera

A Large-Scale, Global Randomized Trial of Coronary Physiology Derived From Conventional Angiography Compared With An Invasive Pressure Wire-Based Approach to Guide Percutaneous Coronary Intervention

一項(xiàng)大規(guī)模全球隨機(jī)試驗(yàn)：比較基于常規(guī)造影衍生的冠狀動(dòng)脈生理學(xué)與基于有創(chuàng)壓力導(dǎo)絲的方法指導(dǎo)經(jīng)皮冠狀動(dòng)脈介入治療

匯報(bào)人：Ajay J. Kirtane

A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina- ORBITA-CTO Trial

穩(wěn)定型心絞痛患者慢性完全閉塞病變經(jīng)皮冠狀動(dòng)脈介入治療的隨機(jī)、安慰劑對(duì)照試驗(yàn)——ORBITA-CTO試驗(yàn)

匯報(bào)人：Sarosh A. Khan

Fractional Flow Reserve or 3d-quantitative Coronary Angiography-Based Vessel-Ffr Guided Revascularization – The Fast Iii Trial

血流儲(chǔ)備分?jǐn)?shù)或基于3D定量冠狀動(dòng)脈造影的血管FFR指導(dǎo)血運(yùn)重建——Fast III試驗(yàn)

匯報(bào)人：Joost Daemen

LBCT IV

北京時(shí)間：3月30日 00:45-1:45

Spironolactone in the Treatment of Heart Failure

螺內(nèi)酯治療心力衰竭

匯報(bào)人：Frank Edelmann

Efficacy and Safety of Sotatercept in Combined Post- and Pre-Capillary Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction: Results From the Phase 2 Cadence TrialSotatercept

在射血分?jǐn)?shù)保留型心力衰竭相關(guān)的毛細(xì)血管前后混合性肺動(dòng)脈高壓中的療效與安全性：2期Cadence試驗(yàn)結(jié)果

匯報(bào)人：Mardi Gomberg-Maitland

Lung Impedance-Guided Therapy in Heart Failure With Preserved Ejection Fraction: Results of a Randomized Clinical Trial

基于肺阻抗監(jiān)測(cè)指導(dǎo)射血分?jǐn)?shù)保留型心力衰竭治療：一項(xiàng)隨機(jī)臨床試驗(yàn)結(jié)果

匯報(bào)人：Michael Kleiner Shochat

Mavacamten in Symptomatic Adolescent Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the Phase 3 Scout-HCM TrialMavacamten

用于有癥狀的青少年梗阻性肥厚型心肌病患者：來(lái)自3期Scout-HCM試驗(yàn)的結(jié)果

匯報(bào)人：Joseph William Rossano

LBCT V

北京時(shí)間：3月30日 6:00-7:00

Redo-Surgery Versus Transcatheter Valve-In-Valve For Mitral Bioprosthetic Dysfunction: The SURVIV Trial

再次外科手術(shù) vs. 經(jīng)導(dǎo)管瓣中瓣技術(shù)治療二尖瓣生物瓣功能障礙：SURVIV試驗(yàn)

匯報(bào)人：Dimytri Siqueira

Transcatheter Aortic Valve Implantation Without Routine Percutaneous Coronary Intervention: A Randomized Controlled Trial

不常規(guī)進(jìn)行經(jīng)皮冠狀動(dòng)脈介入治療的經(jīng)導(dǎo)管主動(dòng)脈瓣植入術(shù)：一項(xiàng)隨機(jī)對(duì)照試驗(yàn)

匯報(bào)人：Michiel Voskuil

Protect The Head To Head Trial: Randomized Comparison of Emboliner Embolic Protection Catheter Vs. Sentinel Cerebral Protection System During Transcatheter Aortic Valve ReplacementProtect The Head to Head

試驗(yàn)：Emboliner栓塞保護(hù)導(dǎo)管與Sentinel腦保護(hù)系統(tǒng)在經(jīng)導(dǎo)管主動(dòng)脈瓣置換術(shù)中的隨機(jī)對(duì)比研究

匯報(bào)人：Adam B. Greenbaum

Two-Year Outcomes After Transcatheter Tricuspid Repair Without Cross-over in the Randomized Tri-fr TrialTri-Fr

隨機(jī)試驗(yàn)中無(wú)交叉治療的經(jīng)導(dǎo)管三尖瓣修復(fù)術(shù)后兩年結(jié)局

匯報(bào)人：Erwan Donal

LBCT VI

北京時(shí)間：3月30日 22:30-23:30

Heartline Study: A Decentralized Randomized Trial of Apple Watch and iPhone-Facilitated AF Detection and Cardiovascular Outcomes in Older Adults Without Known Atrial FibrillationHeartline

研究：一項(xiàng)基于蘋(píng)果手表與iPhone的無(wú)癥狀老年人房顫篩查及心血管結(jié)局分散式隨機(jī)試驗(yàn)

匯報(bào)人：C. Michael Gibson

Digoxin in Rheumatic Heart Disease: A Multi-Center, Randomized, Double Blind, Placebo-controlled Trial

地高辛用于風(fēng)濕性心臟?。阂豁?xiàng)多中心、隨機(jī)、雙盲、安慰劑對(duì)照試驗(yàn)

匯報(bào)人：Ganesan Karthikeyan

Discontinuation of β-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction

急性心肌梗死后病情穩(wěn)定患者停用β受體阻滯劑治療

匯報(bào)人：Joo-Yong Hahn

Effect of Intensive Triglyceride Lowering With Olezarsen on Progression of Coronary Atherosclerosis: A Coronary Cta Substudy of The Essence-TIMI 73b Randomized TrialOlezarsen

強(qiáng)化降低甘油三酯對(duì)冠狀動(dòng)脈粥樣硬化進(jìn)展的影響：Essence-TIMI 73b隨機(jī)試驗(yàn)的冠狀動(dòng)脈CTA亞組研究

匯報(bào)人：Nicholas Marston

LBCT VII

北京時(shí)間：3月31日 00:45-1:45

Primary Efficacy and Safety Results From the Phase 3 Sirolimus-Coated Balloon For Infra-inguinal Peripheral Arterial Disease (SirPAD) Trial

西羅莫司涂層球囊治療腹股溝下外周動(dòng)脈疾病的3期SirPAD試驗(yàn)主要療效與安全性結(jié)果

匯報(bào)人：Stefano Barco

Intravascular Ultrasound Guidance For Complex High-Risk Indicated Procedures – The Ivus Chip Trial

血管內(nèi)超聲指導(dǎo)復(fù)雜高危有指征手術(shù)——Ivus Chip試驗(yàn)

匯報(bào)人：Roberto Diletti

03

特色臨床研究（FCR）

FCR I

北京時(shí)間：3月29日 02:00-03:00

A Prospective Multicenter Registry to Define Coronary Vasomotor Disorders in Ischemia With Nonobstructive Coronary Arteries: Primary Results of Discover Inoca

一項(xiàng)前瞻性多中心注冊(cè)研究旨在明確非阻塞性冠狀動(dòng)脈缺血中的冠狀動(dòng)脈血管舒縮功能障礙：DISCOVER INOCA研究主要結(jié)果

匯報(bào)人：Samit M. Shah

Impact of Ivabradine on Orthostatic Intolerance, Quality of Life and Heart Rate in Post-Covid Postural Orthostatic Tachycardia Syndrome: Results From the Recover-Autonomic Trial

伊伐布雷定對(duì)新冠后體位性心動(dòng)過(guò)速綜合征患者直立不耐受、生活質(zhì)量及心率的影響：RECOVER-AUTONOMIC試驗(yàn)結(jié)果

匯報(bào)人：Saibal Kar

Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Sex Differences in Underlying Causes of Myocardial Infarction With No Obstructive Coronary Arteries

應(yīng)用冠脈光學(xué)相干斷層掃描與心臟磁共振成像探究非阻塞性冠脈心肌梗死病因的性別差異

匯報(bào)人：Harmony R. Reynolds

A Sham Controlled Randomised Trial Evaluating the Safety, Acceptability and Efficacy of Autonomic Neuromodulation Using Trans-Cutaneous Vagal Sensory Stimulation in Uncontrolled Hypertensive Patients

評(píng)估經(jīng)皮迷走神經(jīng)感覺(jué)刺激用于未控制高血壓患者自主神經(jīng)調(diào)節(jié)的安全性、可接受性與有效性：一項(xiàng)假刺激對(duì)照隨機(jī)試驗(yàn)

匯報(bào)人：Ajay K. Gupta

FCR II

北京時(shí)間：3月29日 03:30-04:30

Effects of Tirzepatide Compared With Dulaglutide on Expanded Cardiorenal Outcomes

替西帕肽對(duì)比度拉糖肽對(duì)擴(kuò)展心腎結(jié)局的影響

匯報(bào)人：Steven E. Nissen

Prevalence and Clinical Impact of Hypercortisolism in Individuals With Resistant Hypertension: Primary Results From the Momentum Study難治性高血壓患者中皮質(zhì)醇增多癥的患病率與臨床影響：MOMENTUM研究的主要結(jié)果

匯報(bào)人：Deepak L. Bhatt

Reliability of CAC=0 to Exclude Coronary Plaque in Diverse Global Cohorts: A Global Probability Study of Coronary Artery Disease (GPS-CAD) Analysis

CAC=0在不同種族隊(duì)列中排除冠脈斑塊的可靠性評(píng)估：全球冠狀動(dòng)脈疾病概率研究（GPS-CAD）數(shù)據(jù)分析

匯報(bào)人：Lohendran Baskaran

Community-to-Clinic Linkage Implementation Program to Prevent Hypertension in Barbershops

基于理發(fā)店的社區(qū)-診所聯(lián)動(dòng)高血壓預(yù)防計(jì)劃實(shí)施研究

匯報(bào)人：Joseph E. Ravenell

FCR III

北京時(shí)間：3月30日 02:15-03:15

10-year Follow-up of Clopidogrel Vs Aspirin Monotherapy in Stable Coronary Artery Disease After Percutaneous Coronary Intervention With Drug-eluting Stent

藥物洗脫支架經(jīng)皮冠狀動(dòng)脈介入治療后，氯吡格雷對(duì)比阿司匹林單藥治療穩(wěn)定型冠狀動(dòng)脈疾病的10年隨訪

匯報(bào)人：Hyo-Soo Kim

Coronary CT Derived Fractional Flow Reserve-guided Management of Patients With Stable CAD: 3-year Outcomes From A Multicentre, Pragmatic, Open-label, Randomised Controlled Trial in China

冠狀動(dòng)脈CT衍生的血流儲(chǔ)備分?jǐn)?shù)指導(dǎo)的穩(wěn)定型冠狀動(dòng)脈疾病患者管理：一項(xiàng)中國(guó)多中心、實(shí)用性、開(kāi)放標(biāo)簽、隨機(jī)對(duì)照試驗(yàn)的3年結(jié)果

匯報(bào)人：唐春香 中國(guó)人民解放軍東部戰(zhàn)區(qū)總醫(yī)院

Role of Screening With Coronary Computed Tomography Angiography in Lipid Management in an Asymptomatic Chinese Population: A Community-Based, Parallel-Group, Open-Label, Randomized Clinical Trial (RESPECT2)

冠狀動(dòng)脈CT血管造影篩查在無(wú)癥狀中國(guó)人群血脂管理中的作用：一項(xiàng)基于社區(qū)的、平行組、開(kāi)放標(biāo)簽、隨機(jī)臨床試驗(yàn)（RESPECT2）

匯報(bào)人：郭翔中國(guó)人民解放軍東部戰(zhàn)區(qū)總醫(yī)院

Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure對(duì)高風(fēng)險(xiǎn)糖尿病患者進(jìn)行針對(duì)性評(píng)估以識(shí)別未確診的心力衰竭

匯報(bào)人：Daniel Taylor-Sweet

FCR IV

北京時(shí)間：3月30日 03:45-04:45

Automated Notifications to Improve Referral and Treatment of Severe Aortic Stenosis and Mitral Regurgitation: Outcomes From the Randomized Alert Trial

自動(dòng)化通知改善重度主動(dòng)脈瓣狹窄和二尖瓣反流的轉(zhuǎn)診與治療：隨機(jī)ALERT試驗(yàn)的結(jié)果

匯報(bào)人：Wayne B. Batchelor

A Randomized Controlled Trial of a Novel Just-in-Time Adaptive Mobile Application Intervention to Reduce Sodium Intake and Blood Pressure in Patients With Hypertension

一項(xiàng)關(guān)于新型即時(shí)適應(yīng)性移動(dòng)應(yīng)用程序干預(yù)以降低高血壓患者鈉攝入和血壓的隨機(jī)對(duì)照試驗(yàn)

匯報(bào)人：Michael Dorsch

NOTIFY-HF: A Randomised Pilot Trial of Patient-Facing Heartlogic Alerts in Heart Failure Patients

NOTIFY-HF：一項(xiàng)面向心力衰竭患者的HeartLogic警報(bào)的隨機(jī)試點(diǎn)試驗(yàn)

匯報(bào)人：Joseph Assad

MUTTON-HF (Medically Utilized Tailored Traditional Foods to Optimize Nutrition in Heart Failure): A Randomized Controlled Trial of an Indigenous Food is Medicine Intervention

MUTTON-HF（醫(yī)療化應(yīng)用定制傳統(tǒng)食物以優(yōu)化心力衰竭營(yíng)養(yǎng)）：一項(xiàng)本土食物即藥物的干預(yù)措施隨機(jī)對(duì)照試驗(yàn)

匯報(bào)人：Lauren A. Eberly

FCR V

北京時(shí)間：3月30日 6:00-7:00

Two-Year Outcomes of Transcatheter Tricuspid Valve Replacement For Severe Tricuspid Regurgitation: The TRISCEND II Randomized Trial

經(jīng)導(dǎo)管三尖瓣置換治療重度三尖瓣反流的兩年結(jié)果：TRISCEND II 隨機(jī)試驗(yàn)

匯報(bào)人：Vinod H. Thourani

Efficacy and Safety of BHB/HRS-1893 in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From A 12-week Phase 2 Study

BHB/HRS-1893在有癥狀的梗阻性肥厚型心肌病中的療效與安全性：一項(xiàng)為期12周的2期研究結(jié)果

匯報(bào)人：康連鳴 中國(guó)醫(yī)學(xué)科學(xué)院阜外醫(yī)院

The Role of Atrial Pacing Support in Cardiac Resynchronization Therapy: A Non-inferiority Randomized Trial

心房起搏支持在心臟再同步化治療中的作用：一項(xiàng)非劣效性隨機(jī)試驗(yàn)

匯報(bào)人：Mauro Biffi

Prehospital Heparin Administration in Patients With STEMI Undergoing Primary PCI

行直接經(jīng)皮冠狀動(dòng)脈介入治療的STEMI患者的院前肝素給藥

匯報(bào)人：Misa Fister